Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hereditary cancer predisposition due to variation(s) in the RAD51C gene. Pathogenic germline variation in RAD51C confers an autosomal dominant predisposition to tumor formation at multiple primary sites, including ovarian cancer, triple negative breast cancer and ER negative breast cancer.
No clinical trials have been registered for RAD51C-related cancer predisposition.
2 publications have been identified in PubMed for RAD51C-related cancer predisposition. Research spans Case Report / Case Series (50%) and Epidemiology / Natural History (50%).
Lawrence A (2026). [PMID: 42065091](https://pubmed.ncbi.nlm.nih.gov/42065091/). *ACG Case Rep J*. [Case Report / Case Series]
Nakahara M (2024). [PMID: 39077936](https://pubmed.ncbi.nlm.nih.gov/39077936/). *J Obstet Gynaecol Res*. [Epidemiology / Natural History]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 4:50 AM UTC
Common questions about RAD51C-related cancer predisposition